Company Description
Chimera Investment Corporation operates as a real estate investment trust (REIT) in the United States.
The company, through its subsidiaries, invests in a portfolio of mortgage assets, including residential mortgage loans, agency residential mortgage-backed securities, non-agency residential mortgage-backed securities, agency mortgage-backed securities secured by pools of commercial mortgage loans, business purpose and investor loans, residential transition loans, and other real estate related securities.
It invests in investment grade, non-investment grade, and non-rated securities. The company qualifies as a REIT for federal income tax purposes.
As a REIT, it intends to distribute at least 90% of its taxable income as dividends to shareholders. Chimera Investment Corporation was incorporated in 2007 and is headquartered in New York, New York.
Country | United States |
Founded | 2007 |
IPO Date | Nov 16, 2007 |
Industry | REIT - Mortgage |
Sector | Real Estate |
Employees | 77 |
CEO | Phillip Kardis |
Contact Details
Address: 630 Fifth Avenue, Suite 2400 New York, New York 10111 United States | |
Phone | 888 895 6557 |
Website | chimerareit.com |
Stock Details
Ticker Symbol | CIM |
Exchange | NYSE |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001409493 |
CUSIP Number | 16934Q802 |
ISIN Number | US16934Q8024 |
Employer ID | 26-0630461 |
SIC Code | 6798 |
Key Executives
Name | Position |
---|---|
Phillip John Kardis II, Esq., J.D. | President, Chief Executive Officer and Director |
Subramaniam Viswanathan | Chief Financial Officer and Principal Accounting Officer |
Miyun Sung J.D. | Chief Legal Officer and Corporate Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 24, 2025 | ARS | Filing |
Apr 24, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 24, 2025 | DEF 14A | Other definitive proxy statements |
Apr 17, 2025 | SCHEDULE 13G/A | Filing |
Apr 11, 2025 | 8-K | Current Report |
Apr 8, 2025 | 8-K | Current Report |
Mar 25, 2025 | 8-K | Current Report |
Mar 20, 2025 | 8-K | Current Report |
Mar 3, 2025 | 8-K | Current Report |
Feb 19, 2025 | 10-K | Annual Report |